Other risks include inevitable patent cliffs. Amgen is facing the loss of exclusivity for top-selling Prolia and Xgeva in 2025, and Enbrel and Otezla in 2028. Other risks include FDA regulatory ...

Less than a decade since it secured its first FDA approval for a biosimilar, Amgen’s portfolio of the copycat drugs is growing and making strong contributions to the company’s top line.

Amgen Inc.'s (NASDAQ:AMGN) dividend will be increasing from last year's payment of the same period to $2.38 on 7th of March. This takes the annual payment to 3.1% of the current stock price, which ...

All of a sudden, Amgen stock is up 15% since late December to around $299. Its rise helped push up the healthcare sector up just over 7% since hitting a bottom in late December. The better-than ...

My name is Julianne, and I will be your conference facilitator today for Amgen's fourth quarter and full year 2024 financial results conference call. All lines have been placed on mute to prevent ...

However, weakness in some key brands like Otezla is a headwind. Also, sales of Amgen’s best-selling drugs, Prolia and Xgeva, are expected to decline in 2025 due to biosimilar competition.

In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other stocks that Jim Cramer discusses that are leading the Dow higher in 2025. On Thursday ...

Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis. The US biotech has just ...

Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...

Metabolic engineering is the use of genetic engineering to modify the metabolism of an organism. It can involve the optimization of existing biochemical pathways or the introduction of pathway ...